5-Amino-1MQ / SLU-PP-332 Blend

5-Amino-1MQ / SLU-PP-332 Blend combines a small-molecule NNMT inhibitor with a synthetic ERR (estrogen-related receptor) agonist studied as an exercise mimetic. 5-Amino-1MQ has been studied, mainly in preclinical and early human contexts, for effects on adipocyte metabolism through inhibition of nicotinamide N-methyltransferase. SLU-PP-332 is a considerably newer compound described in rodent studies as activating pathways associated with mitochondrial biogenesis and energy expenditure, similar to those engaged during endurance exercise; it has not been evaluated in any published human trial. The blend pairs a metabolic enzyme-inhibition strategy with an exercise-mimetic strategy, but because SLU-PP-332 lacks human data entirely, claims about this combination in people are speculative and should be treated with substantial caution. Reported benefits include 5-amino-1mq is studied for potential effects on adipocyte metabolism and body composition, slu-pp-332 is described in preclinical rodent studies as mimicking some metabolic effects of endurance exercise, targets two distinct tissues, adipose and skeletal muscle, in a single product.

Reported ranges run 25-100 mg. A low protocol is 25 mg once daily, and a high protocol is 100 mg once daily. This is reference information, not a dosing recommendation.

5-Amino-1MQ's half-life in humans has not been formally established, though once-daily dosing is commonly described. SLU-PP-332 has no published human pharmacokinetic data; rodent studies describe short-acting exposure requiring frequent dosing.. That is what sets the dosing frequency, and it is why the timing guidance is morning.

Subcutaneous: into fat, under the skin. 5-Amino-1MQ is often studied via the oral route; SLU-PP-332 has no established human route or dosing, so this subcutaneous blend reflects vendor formulation rather than clinical precedent.

4-8 weeks on, followed by 2-4 weeks off. Cycling for this blend is drawn largely from vendor and anecdotal sources rather than clinical protocols, particularly for SLU-PP-332, which has no established human dosing regimen.

Reported side effects include human side-effect data for slu-pp-332 do not exist in the published literature, 5-amino-1mq's human safety data remain limited to small or short-term studies, injection site irritation, unknown risks from combining an entirely preclinical compound with 5-amino-1mq. Evidence level for this compound is emerging research.